ENOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Enovis Corp (ENOV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown positive momentum following strong earnings, favorable analyst ratings, and improving financial metrics. While there are some concerns about net income decline, the company's growth in revenue and gross margin, coupled with its strong position in the reconstructive devices sector, make it a compelling investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral, suggesting no overbought or oversold conditions. The stock is trading near its resistance level (R1: 24.963), with potential to test R2: 25.971. Converging moving averages signal a potential trend continuation.
Enovis exceeded Q4 2025 earnings expectations, with adjusted EPS of $0.95 and a 14% stock price increase post-announcement.
Analysts have consistently rated the stock as a Buy, with price targets ranging from $40 to $
Front Street Capital Management increased its holdings significantly, signaling institutional confidence.
The company has a strong track record of beating EPS estimates.
Net income dropped significantly (-25.98% YoY) in Q4
EPS also declined (-27.66% YoY), reflecting profitability challenges.
Sector rotation and potential ACA and Medicare changes could pose risks.
In Q4 2025, revenue increased by 2.64% YoY to $576 million, and gross margin improved by 4.18% YoY to 52.84%. However, net income dropped by 25.98% YoY to -$520.59 million, and EPS declined by 27.66% YoY to -9.1. The company demonstrated growth in top-line performance but faced challenges in profitability.
Analysts have a positive outlook on Enovis, with multiple Buy ratings and price targets ranging from $40 to $50. Analysts highlight the company's improving financial profile, recovering end markets, and strong positioning in the MedTech sector as key drivers for growth.
